Navidea Biopharmaceuticals (NAVB) 10-Q 9 May 18 2018 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Mar. 31, 2018	May 01, 2018
Document Information [Line Items]
Entity Registrant Name	NAVIDEA BIOPHARMACEUTICALS, INC.
Entity Central Index Key	810,509
Trading Symbol	navb
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Common Stock, Shares Outstanding (in shares)		162,959,731
Document Type	10-Q
Document Period End Date	Mar. 31, 2018
Document Fiscal Year Focus	2,018
Document Fiscal Period Focus	Q1
Amendment Flag	false

Consolidated Balance Sheets (Cu

Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Mar. 31, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 817,016	$ 2,795,006
Available-for-sale securities	1,397,428	1,797,604
Accounts and other receivables	12,954,997	8,137,872
Prepaid expenses and other	1,058,069	1,101,923
Total current assets	16,227,510	13,832,405
Property and equipment	1,206,058	1,206,058
Less accumulated depreciation and amortization	999,928	969,357
Property and equipment, net	206,130	236,701
Patents, trademarks and license agreements	480,404	480,404
Less accumulated amortization	29,664	22,248
Patents, trademarks and license agreements, net	450,740	458,156
Guaranteed earnout receivable		4,809,376
Other assets	1,437,847	1,444,798
Total assets	18,322,227	20,781,436
Current liabilities:
Accounts payable	700,232	855,043
Accrued liabilities and other	1,793,965	1,857,848
Notes payable	2,276,926	2,353,639
Terminated lease liability, current	110,784	107,215
Accrued loss for CRG litigation	7,153,000	2,887,566
Liabilities associated with discontinued operations, current		7,092
Total current liabilities	12,034,907	8,068,403
Terminated lease liability	572,614	588,092
Deferred revenue	700,000	11,024
Other liabilities	65,349	65,587
Total liabilities	13,372,870	8,733,106
Commitments and contingencies (Note 11)
Stockholders’ equity:
Preferred stock; $.001 par value; 5,000,000 shares authorized; no shares issued or outstanding at March 31, 2018 and December 31, 2017
Common stock; $.001 par value; 300,000,000 shares authorized; 162,959,731 and 162,206,646 shares issued and outstanding at March 31, 2018 and December 31, 2017, respectively	162,960	162,207
Additional paid-in capital	331,467,199	331,128,787
Accumulated deficit	(327,346,921)	(319,908,968)
Accumulated other comprehensive loss	(2,572)	(2,396)
Total Navidea stockholders' equity	4,280,666	11,379,630
Noncontrolling interest	668,691	668,700
Total stockholders’ equity	4,949,357	12,048,330
Total liabilities and stockholders’ equity	$ 18,322,227	$ 20,781,436

Consolidated Balance Sheets (C3

Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Mar. 31, 2018	Dec. 31, 2017
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	300,000,000	300,000,000
Common stock, shares issued (in shares)	162,959,731	162,206,646
Common stock, shares outstanding (in shares)	162,959,731	162,206,646

Consolidated Statements of Oper

Consolidated Statements of Operations (Unaudited) - USD ($)		3 Months Ended
		Mar. 31, 2018		Mar. 31, 2017
Revenue:
Tc99m tilmanocept royalty revenue		$ 16,000
Grant and other revenue		275,650		$ 580,030
Revenue		276,445		580,030
Cost of goods sold		318
Gross profit		276,127		580,030
Operating expenses:
Research and development expenses		998,956		705,274
Selling, general and administrative		1,776,372		3,022,434
Total operating expenses		2,775,328		3,727,708
Loss from operations	[1]	(2,499,201)		(3,147,678)
Other income (expense):
Interest income, net		31,387		24,112
Change in fair value of financial instruments				140,485
Loss on extinguishment of debt		(4,265,434)		(1,314,102)
Other, net		(4,714)		(21,604)
Total other expense, net		(4,238,761)	[2]	(1,171,109)
Loss before income taxes		(6,737,962)		(4,318,787)
Benefit from income taxes		0		1,454,172
Loss from continuing operations		(6,737,962)		(2,864,615)
Discontinued operations, net of tax effect:
Loss from discontinued operations				(255,861)
Gain on sale				88,701,501
Net (loss) income		(6,737,962)		85,581,025
Less loss attributable to noncontrolling interest		(9)		(202)
Net (loss) income attributable to common stockholders		$ (6,737,953)		$ 85,581,227
(Loss) income per common share (basic):
Continuing operations (in dollars per share)		$ (0.04)		$ (0.02)
Discontinued operations (in dollars per share)				0.55
Attributable to common stockholders (in dollars per share)		$ (0.04)		$ 0.53
Weighted average shares outstanding (basic) (in shares)		162,269,012		160,376,476
(Loss) income per common share (diluted):
Continuing operations (in dollars per share)		$ (0.04)		$ (0.02)
Discontinued operations (in dollars per share)				0.54
Attributable to common stockholders (in dollars per share)		$ (0.04)		$ 0.52
Weighted average shares outstanding (diluted) (in shares)		162,269,012		164,871,955
Royalty [Member]
Revenue:
Tc99m tilmanocept royalty revenue		$ 795
[1]	Loss from operations does not reflect the allocation of certain selling, general and administrative expenses, excluding depreciation and amortization, to our individual reportable segments, other than those expenses directly incurred by MT.
[2]	Amounts consist primarily of losses on debt extinguishment and changes in fair value of financial instruments, which are not currently allocated to our individual reportable segments.

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income (Loss) (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Net (loss) income	$ (6,737,962)	$ 85,581,025
Unrealized loss on available-for-sale securities	(176)
Comprehensive (loss) income	$ (6,738,138)	$ 85,581,025

Consolidated Statement of Stock

Consolidated Statement of Stockholders' Equity (Deficit) (Unaudited) - 3 months ended Mar. 31, 2018 - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Noncontrolling Interest [Member]	Total
Balance (in shares) at Dec. 31, 2017	162,206,646
Balance at Dec. 31, 2017	$ 162,207	$ 331,128,787	$ (319,908,968)	$ (2,396)	$ 668,700	$ 12,048,330
Impact of adoption of ASC Topic 606 at Dec. 31, 2017			(700,000)			(700,000)
Issued stock in payment of employee bonuses (in shares)	458,401
Issued stock in payment of employee bonuses	$ 458	164,563				165,021
Issued restricted stock (in shares)	200,000
Issued restricted stock	$ 200					$ 200
Issued stock to 401(k) plan (in shares)	94,684					94,684
Issued stock to 401(k) plan	$ 95	35,885				$ 35,980
Stock compensation expense		137,964				137,964
Net loss			(6,737,953)		(9)	(6,737,962)
Unrealized loss on available-for-sale securities				(176)		(176)
Total comprehensive loss						(6,738,138)
Balance (in shares) at Mar. 31, 2018	162,959,731
Balance at Mar. 31, 2018	$ 162,960	$ 331,467,199	$ (327,346,921)	$ (2,572)	$ 668,691	$ 4,949,357

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Cash flows from operating activities:
Net (loss) income	$ (6,737,962)	$ 85,581,025
Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities:
Depreciation and amortization	37,987	86,535
Loss on disposal and abandonment of assets		100,270
Compounded interest on long term debt	41,624	143,114
Stock compensation expense	137,964	147,165
Change in fair value of financial instruments		(140,485)
Loss on extinguishment of debt	4,265,434	1,314,102
Issued warrants in connection with Asset Sale		3,337,187
Value of stock issued to directors		10,500
Value of stock issued to employees	165,021	367,812
Value of stock issued to 401(k) plan for employer matching contributions	35,980
Changes in operating assets and liabilities:
Accounts and other receivables	(7,749)	(14,821,403)
Inventory		1,470,078
Prepaid expenses and other assets	50,805	(65,632)
Accounts payable	(154,811)	(3,837,463)
Accrued and other liabilities	(79,109)	(3,719,024)
Deferred revenue	(15,037)	(2,315,037)
Net cash (used in) provided by operating activities	(2,259,853)	67,658,744
Cash flows from investing activities:
Maturities of available-for-sale securities	400,000
Net cash provided by investing activities	400,000
Cash flows from financing activities:
Proceeds from issuance of common stock	200	54,119
Payment of debt-related costs		(1,314,102)
Principal payments on notes payable	(118,337)	(59,498,721)
Net cash used in financing activities	(118,137)	(60,758,704)
Net (decrease) increase in cash, cash equivalents and restricted cash	(1,977,990)	6,900,040
Cash, cash equivalents and restricted cash, beginning of period	2,795,006	6,540,578
Cash, cash equivalents and restricted cash, end of period	$ 817,016	$ 13,440,618

Note 1 - Summary of Significant

Note 1 - Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Significant Accounting Policies [Text Block]	1. Summary of Significant Accounting Policies a. Basis of Presentation: March 31, 2018 three March 31, 2018 2017 March 31, 2018 not December 31, 2017, 10 Our consolidated financial statements include the accounts of Navidea and our wholly owned subsidiaries, Navidea Biopharmaceuticals Limited and Cardiosonix Ltd, as well as those of our majority-owned subsidiary, Macrophage Therapeutics, Inc. (“MT”). All significant inter-company accounts were eliminated in consolidation. Cardiosonix was legally dissolved in September 2017. On March 3, 2017, November 23, 2016 ( 414, 414” ® Upon closing of the Asset Sale, the Supply and Distribution Agreement dated November 15, 2007, 414 no Our consolidated balance sheets and statements of operations have been reclassified, as required, for all periods presented to reflect the Business as a discontinued operation. Cash flows associated with the operation of the Business have been combined with operating, investing and financing cash flows, as appropriate, in our consolidated statements of cash flows. See Note 3. Certain prior period amounts also have been reclassified to conform with the current year’s presentation, including the adoption of Accounting Standards Update (“ASU”) No. 2014 09, Revenue from Contracts with Customers b. Financial Instruments and Fair Value: 1 3 three Level 1 Level 2 not Level 3 A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. In determining the appropriate levels, we perform a detailed analysis of the assets and liabilities whose fair value is measured on a recurring basis. At each reporting period, all assets and liabilities for which the fair value measurement is based on significant unobservable inputs or instruments which trade infrequently and therefore have little or no 3. 5. The following methods and assumptions were used to estimate the fair value of each class of financial instruments: ( 1 Cash, available-for-sale securities, accounts and other receivables, and accounts payable: March 31, 2018 December 31, 2017, $96,000 2016. ( 2 Notes payable: March 31, 2018 December 31, 2017 March 31, 2018 December 31, 2017, 3 March 31, 2018 December 31, 2017, March 31, 2018, $2.3 $2.3 December 31, 2017, $2.4 $2.4 9. ( 3 Derivative liabilities: $63,000 March 31, 2018 December 31, 2017 March 31, 2018 December 31, 2017 5. ( 4 Warrants: March 2017, 414 five 10 1 $1.50 414 $3.3 three March 31, 2017. $334,000, 13. c. Revenue Recognition: We also earn revenues related to our licensing and distribution agreements. The consideration we are eligible to receive under our licensing and distribution agreements typically includes upfront payments, reimbursement for research and development costs, milestone payments, and royalties. Each licensing and distribution agreement is unique and requires separate assessment in accordance with current accounting standards. See Note 4. d. Recent ly Adopted Accounting Standards : May 2014, 2014 09, Revenue from Contracts with Customers (Topic 606 2014 09 2014 09 five may 2014 09, 606 2014 09 2014 09 2014 09 December 15, 2017, In March 2016, No. 2016 08, Revenue from Contracts with Customers – Principal versus Agent Considerations (Reporting Revenue Gross versus Net) 2016 08 not 2016 08 No. 2014 09, Revenue from Contracts with Customers (Topic 606 not 2016 08 2014 09, one No. 2015 14, Revenue from Contracts with Customers – Deferral of the Effective Date December 15, 2017, December 15, 2016, In April 2016, No. 2016 10, Revenue from Contracts with Customers – Identifying Performance Obligations and Licensing 2016 10 not 2016 10 No. 2014 09, Revenue from Contracts with Customers (Topic 606 not 2016 10 2014 09, one No. 2015 14, Revenue from Contracts with Customers – Deferral of the Effective Date December 15, 2017, December 15, 2016, In May 2016, No. 2016 12, Revenue from Contracts with Customers – Narrow-Scope Improvements and Practical Expedients 2016 12 not 606, 2016 12 No. 2014 09, Revenue from Contracts with Customers (Topic 606 not 2016 12 2014 09, one No. 2015 14, Revenue from Contracts with Customers – Deferral of the Effective Date December 15, 2017, December 15, 2016, In December 2016, No. 2016 20, Technical Corrections and Improvements to Topic 606, 2016 20 not 606, 606, 2016 20 No. 2014 09, Revenue from Contracts with Customers (Topic 606 not 2016 12 2014 09, one No. 2015 14, Revenue from Contracts with Customers – Deferral of the Effective Date December 15, 2017, December 15, 2016, We adopted ASU 2014 09, 2016 08, 2016 10, 2016 12 2016 20, January 1, 2018 2014 09 $700,000. 4. In November 2016, No. 2016 18, Statement of Cash Flows – Restricted Cash 2016 18 2016 18 December 15, 2017, 2016 18 2016 18 January 1, 2018. 2016 18 $5.0 three March 31, 2017. In March 2018, No. 2018 05, Income Taxes (Topic 740 No. 118. 2018 05 740 No. 118. 2018 05 740 2018 05 March 2018 not

Note 2 - Liquidity

Note 2 - Liquidity	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Substantial Doubt about Going Concern [Text Block]	2. Liquidity As disclosed in the Company’s Annual Report on Form 10 December 2017, $66.0 $66.0 2017. $59.0 March 2017, $7.0 not June 2016 $4.1 $66.0 $4.1 $4.1 $7.0 On January 16, 2018, $66.0 $4.1 June 2016, $2.9 March 26, 2018, $7.7 April 2, 2018, $4.1 June 2016 $66.0 On April 2, 2018, 414 $6.0 not $7.1 414 414 414 April 9, 2018, $7.1 $4.1 $59.0 On April 12, 2018 2017, $66.0 $66.0 $4.1 June 2016 $66.0 $66.0 $7.1 414 no In a related proceeding before the Ohio Court, initially filed in 2016, 2017, $66.0 not $4.1 $4.1 On April 11, 2018, not $7.1 414 April 16, 2018, April 27, 2018. May 2, 2018, May 21, 2018. In addition, the Company previously was a party to a Loan Agreement with Platinum-Montaur Life Sciences LLC (“Platinum-Montaur”), an affiliate of Platinum Management (NY) LLC, Platinum Partners Value Arbitrage Fund L.P. (“PPVA”), Platinum Partners Liquid Opportunity Master Fund L.P., Platinum Liquid Opportunity Management (NY) LLC, and Montsant Partners LLC (collectively, “Platinum”) (the “Platinum Loan Agreement”) and a Third Amended and Restated Promissory Note (“Platinum Note”) given by Navidea in favor of Platinum-Montaur. In connection with the closing of the Asset Sale to Cardinal Health 414, $7.7 $1.9 not On November 2, 2017, $1.9 March 3, 2017, December 6, 2017. January 26, 2018. March 9, 2018, April 6, 2018. April 30, 2018 no The Company has experienced recurring net losses and recent unfavorable court rulings, and has used significant cash to fund its operations, all of which are factors that raise substantial doubt about our ability to continue as a going concern. Following the completion of the Amendment, including receipt of approximately $6.0 414 414 twelve 10

Note 3 - Discontinued Operation

Note 3 - Discontinued Operations	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]	3 . Discontinued Operations On March 3, 2017, 414 ® 414 $80.6 $3.0 April 2, 2018, 414 $6.0 not $7.1 414 414 414 We recorded a net gain on the sale of the Business of $88.7 three March 31, 2017, $16.5 $3.3 414, $2.0 $800,000 $4.6 As a result of the Asset Sale, we reclassified certain assets and liabilities as assets and liabilities associated with discontinued operations. The following liabilities have been segregated and included in liabilities associated with discontinued operations, as appropriate, in the consolidated balance sheets: March 31, 2018 December 31, 2017 Accrued liabilities $ — $ 7,092 Liabilities associated with discontinued operations, current $ — $ 7,092 In addition, we reclassified certain revenues and expenses related to the Business to discontinued operations for all periods presented, including interest expense related to the CRG and Platinum debt obligations as required by current accounting guidance. The following amounts have been segregated from continuing operations and included in discontinued operations in the consolidated statements of operations: Three Months Ended March 31, 2018 2017 Lymphoseek sales revenue $ — $ 2,917,213 Cost of goods sold — 364,192 Gross profit — 2,553,021 Operating expenses: Research and development — 283,533 Selling, general and administrative — 820,203 Total operating expenses — 1,103,736 Income from discontinued operations — 1,449,285 Interest expense — (1,718,506 ) Loss before income taxes — (269,221 ) Benefit from income taxes — 13,360 Loss from discontinued operations $ — $ (255,861 )

Note 4 - Revenue From Contracts

Note 4 - Revenue From Contracts With Customers	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Revenue from Contract with Customer [Text Block]	4 . Revenue from Contracts with Customers The Company adopted ASU 2014 09, January 1, 2018, three March 31, 2018 January 1, 2018 not January 1, 2018. We earn revenues related to our licensing and distribution agreements. The terms of these agreements may The cumulative effect of the change on accumulated deficit as of January 1, 2018 $700,000, $100,000 Tc99m June 2017, $600,000 Tc99m August 2014. not P re - Adoption P ost - Adoption Change Deferred revenue $ 26,061 $ 726,061 $ 700,000 Accumulated deficit (319,908,968 ) (320,608,968 ) (700,000 ) During the three March 31, 2018, $16,000. not Navidea is focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. We manage our business based on two Tc99m Tc99m one Tc99 three March 31, 2018. T hree Months Ended March 31, 2018 Diagnostics Therapeutics Total Tc99m tilmanocept royalty revenue: Europe $ 795 $ — $ 795 India — — — China — — — Total $ 795 $ — $ 795 Other revenue: Additional stability studies $ 15,037 $ — $ 15,037 The following economic factors affect the nature, amount, timing and uncertainty of the Company’s revenue and cash flows as indicated: Geographical L ocation of C ustomers: may may Status of Regulatory Approval: Tc99m Tc99m not may The following table summarizes the changes in contract liabilities, the current portion of which is included in accrued liabilities and other in the consolidated balance sheets, during the three March 31, 2018 2017: Three Months Ended March 31, 2018 2017 Total deferred revenue, beginning of period $ 26,061 $ 41,098 Impact of adoption of ASU 2014-09 and related standards 700,000 — Revenue recognized from satisfaction of performance obligations (15,037 ) (15,037 ) Total deferred revenue, end of period $ 711,024 $ 26,061 Currently, the Company recognizes revenue from up-front license fees and pre-market milestones after the cash has been received from its customers and the performance obligations have been met. Payments for sales-based royalties and milestones are generally received after the related revenue has been recognized and invoiced. Normal payment terms generally range from 15 90 not three March 31, 2018. During the three March 31, 2018, not Up-front and milestone payments received related to our license and distribution agreements in India and China are deferred until Tc99m not Tc99m not no not eight 10 The transaction price of a contract is the amount of consideration to which the Company expects to be entitled in exchange for transferring promised goods or services to a customer. Transaction prices do not third not When estimating a contract’s transaction price, the Company considers all the information (historical, current, and forecasted) that is reasonably available to it and identifies possible consideration amounts. Most of the Company’s contracts with customers include both fixed and variable components of the transaction price. Under those contracts, some or all of the consideration for satisfied performance obligations is contingent on events over which the Company has no Tc99m The milestone payments have a binary outcome (that is, the Company will either receive all or none not Royalties are estimated based on the expected value method because they are based on a variable amount of sales representing a range of possible outcomes. However, when taking into account the constraint on variable consideration, the estimate of future royalties included in the transaction price is generally $0. Tc99m not no no Up-front fees, milestones and royalties are generally non-refundable. Therefore, the Company does not Through March 31, 2018, not

Note 5 - Fair Value

Note 5 - Fair Value	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Fair Value Disclosures [Text Block]	5 . Fair Value MT issued warrants to purchase MT Common Stock with certain characteristics including a net settlement provision that require the warrants to be accounted for as a derivative liability at fair value on the consolidated balance sheets. The estimated fair value of the MT warrants is $63,000 March 31, 2018 December 31, 2017, 1 The following tables set forth, by level, financial liabilities measured at fair value on a recurring basis: Liabilities Measured at Fair Value on a Recurring Basis as of March 31, 201 8 and December 31, 2017 Description Quoted Prices in Active Markets for Identical Liabilities (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Total Liability related to MT warrants $ — $ — $ 63,000 $ 63,000 a. Valuation Processes-Level 3 third b. Sensitivity Analysis-Level 3 may may not There were no 1 2 three March 31, 2018 2017. no 1 2 three March 31, 2018 2017. 3 3 three March 31, 2018 2017 $0 $140,000,

Note 6 - Stock-based Compensati

Note 6 - Stock-based Compensation	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	6 . Stock-Based Compensation For the three March 31, 2018 2017, $138,000 $147,000, not three March 31, 2018 2017. In connection with Dr. Goldberg’s appointment as Chief Executive Officer of the Company in September 2016, 5,000,000 100% five $2.50 tenth not 2014 “2014 March 2018, 10 2014 15 2014 A summary of the status of our stock options as of March 31, 2018, three T hree Months Ended March 31, 2018 Number of Options Weighted Average Exercise Price Weighted Average Remaining Contractual Life (years) Aggregate Intrinsic Value Outstanding at beginning of period 3,687,679 $ 1.50 Granted 470,000 0.53 Exercised — — Canceled and Forfeited (5,000 ) 0.51 Expired — — Outstanding at end of period 4,152,679 $ 1.39 6.8 $ — Exercisable at end of period 2,159,746 $ 2.06 4.5 $ — A summary of the status of our unvested restricted stock as of March 31, 2018, three Three Months Ended March 31, 2018 Number of Shares Weighted Average Grant-Date Fair Value Unvested at beginning of period 150,000 $ 0.51 Granted 200,000 0.37 Vested (100,000 ) 0.43 Forfeited — — Unvested at end of period 250,000 $ 0.42 As of March 31, 2018, $195,000 1.3

Note 7 - Earnings (Loss) Per Sh

Note 7 - Earnings (Loss) Per Share	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Earnings Per Share [Text Block]	7 . (Loss) Earnings Per Share Basic (loss) earnings per share is calculated by dividing net (loss) income attributable to common stockholders by the weighted-average number of common shares and, except for periods with a loss from operations, participating securities outstanding during the period. Diluted (loss) earnings per share reflects additional common shares that would have been outstanding if dilutive potential common shares had been issued. Potential common shares that may The following table sets forth the reconciliation of the weighted average number of common shares outstanding used to compute basic and diluted (loss) earnings per share for the three March 31, 2017 2016: Three Months Ended March 31 , 2018 2017 Weighted average shares outstanding, basic 162,269,012 160,376,476 Dilutive shares related to warrants — 4,288,479 Unvested restricted stock — 207,000 Weighted average shares outstanding, diluted 162,269,012 164,871,955 Diluted (loss) earnings per common share for the three March 31, 2018 2017 15.0 15.9 The Company’s unvested restricted stock awards contain nonforfeitable rights to dividends or dividend equivalents, whether paid or unpaid (referred to as “participating securities”). Therefore, the unvested restricted stock awards are required to be included in the number of shares outstanding for both basic and diluted earnings per share calculations. However, due to our loss from continuing operations, 250,000 207,000 three March 31, 2018 2017,

Note 8 - Accounts Payable, Accr

Note 8 - Accounts Payable, Accrued Liabilities and Other	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]	8 . Accounts Payable , Accrued Liabilities and Other At March 31, 2018, $96,000 2016. Accrued liabilities and other at March 31, 2018 December 31, 2017 $956,000 $975,000,

Note 9 - Notes Payable

Note 9 - Notes Payable	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Debt Disclosure [Text Block]	9 . Notes Payable Platinum In July 2012, $50 414, $7.7 $1.9 not On November 2, 2017, $1.9 March 3, 2017, December 6, 2017. January 26, 2018. March 9, 2018, April 6, 2018. April 30, 2018 no During the three March 31, 2018 2017, $42,000 $143,000 March 31, 2018, $2.1 The Platinum Note is reflected on the consolidated balance sheets at its estimated fair value, which includes the estimated fair value of the embedded conversion option of $0 March 31, 2018 December 31, 2017. $0 $140,000, three March 31, 2018 2017. $2.1 $2.0 March 31, 2018 December 31, 2017, Capital Royalty Partners II, L.P. As disclosed in the Company’s Annual Report on Form 10 December 2017, $66.0 $66.0 2017. $59.0 March 2017, $7.0 not June 2016 $4.1 $66.0 $4.1 $4.1 $7.0 On January 16, 2018, $66.0 $4.1 June 2016, $2.9 March 26, 2018, $7.7 April 2, 2018, $4.1 June 2016 $66.0 On April 9, 2018, $7.1 $4.1 $59.0 On April 12, 2018 2017, $66.0 $66.0 $4.1 June 2016 $66.0 $66.0 $7.1 414 no In a related proceeding before the Ohio Court, initially filed in 2016, 2017, $66.0 not $4.1 $4.1 On April 11, 2018, not $7.1 414 April 16, 2018, April 27, 2018. May 2, 2018, May 21, 2018. 2, 11 17 IPFS Corporation In December 2016, $348,000 8.99%. eight $45,000, July 2017. In November 2017, $396,000 4.0%. ten $40,000, August 2018. $200,000 $318,000 March 31, 2018 December 31, 2017, Summary During the three March 31, 2018 2017, $44,000 $1.7 $42,000 $143,000 three March 31, 2018 2017,

Note 10 - Terminated Lease Liab

Note 10 - Terminated Lease Liability	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Terminated Lease Liability Disclosure [Text Block]	10. Terminated Lease Liability Effective June 1, 2017, 5600 4995 no October 2022. In accordance with current accounting guidance, the Company initially recorded a total liability of $1.0 $399,000 $706,000. December 31, 2017. A summary of the changes in our terminated lease liability during the three March 31, 2018 Terminated Lease Liability Total liability, January 1, 2018 $ 695,307 Changes in estimated future payments (44,755 ) Payments under Blazer lease (93,217 ) Receipts from subtenant 117,373 Accretion of liability 8,690 Total liability, March 31, 2018 $ 683,398

Note 11 - Commitments and Conti

Note 11 - Commitments and Contingencies	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	1 1 . Commitments and Contingencies We are subject to legal proceedings and claims that arise in the ordinary course of business. Sinotau Litigation – NAV4694 On August 31, 2015, NAV4694 September 2016, In October 2017, NAV4694, NAV4694 not In April 2018, NAV4694, NAV4694 CRG Litigation As disclosed in the Company’s Annual Report on Form 10 December 2017, $66.0 $66.0 2017. $59.0 March 2017, $7.0 not June 2016 $4.1 $66.0 $4.1 $4.1 $7.0 On January 16, 2018, $66.0 $4.1 June 2016, $2.9 March 26, 2018, $7.7 April 2, 2018, $4.1 June 2016 $66.0 On April 9, 2018, $7.1 $4.1 $59.0 On April 12, 2018 2017, $66.0 $66.0 $4.1 June 2016 $66.0 $66.0 $7.1 414 no In a related proceeding before the Ohio Court, initially filed in 2016, 2017, $66.0 not $4.1 $4.1 On April 11, 2018, not $7.1 414 April 16, 2018, April 27, 2018. May 2, 2018, May 21, 2018. 2, 9 17 Sinotau Litigation – Tc99m Tilmanocept On February 1, 2017, Tc99m 414. February 3, 2017, March 6, 2017. March 3, 2017. March 6, 414 February 2, 2017. July 12, 2017, July 27, 2017 60 February 8, 2018, February 17, 2018, February 20, 2018, Platinum-Montaur Life Sciences LLC On November 2, 2017, $1.9 March 3, 2017, December 6, 2017. January 26, 2018. March 9, 2018, April 6, 2018. April 30, 2018 no In accordance with ASC Topic 450, Contingencies not

Note 12 - Equity Instruments

Note 12 - Equity Instruments	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	1 2 . Equity Instruments During the three March 31, 2018 2017, 458,401 707,353 $165,000 $368,000, 2017, 2016 2015 During the three March 31, 2018, 94,684 401 $36,000. During the three March 31, 2017, 16,406 $10,500 not three March 31, 2018.

Note 13 - Stock Warrants

Note 13 - Stock Warrants	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Stock Warrants Disclosure [Text Block]	1 3 . Stock Warrants In January 2017, 5,411,850 5,411,850 $54,119. In March 2017, 414 five 10 1 $1.50 five 77% five 2%. 414 $3.3 three March 31, 2017. $334,000, three March 31, 2017. At March 31, 2018, 16.9 $0.01 $3.04 $1.19 three 17 In addition, at March 31, 2018, 300 $2,000

Note 14 - Income Taxes

Note 14 - Income Taxes	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Income Tax Disclosure [Text Block]	1 4 . Income Taxes Income taxes are accounted for under the asset and liability method. Deferred tax assets (“DTAs”) and deferred tax liabilities (“DTLs”) are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, and operating loss and tax credit carryforwards. DTAs and DTLs are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on DTAs and DTLs of a change in tax rates is recognized in income in the period that includes the enactment date. Current accounting standards require a valuation allowance against DTAs if, based on the weight of available evidence, it is more likely than not may not March 31, 2018 December 31, 2017, In assessing the realizability of DTAs, management considers whether it is more likely than not not not not March 31, 2018 The Tax Cuts and Jobs Act was signed into law on December 22, 2017. 35% 21%, January 1, 2018. 2018, 2019 2020. may 2018 2020, 50 2018, 2019 2020 2021. $1.2 March 31, 2018 December 31, 2017. may Current accounting standards include guidance on the accounting for uncertainty in income taxes recognized in the financial statements. Such standards also prescribe a recognition threshold and measurement model for the financial statement recognition of a tax position taken, or expected to be taken, and provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition. The Company believes that the ultimate deductibility of all tax positions is highly certain, although there is uncertainty about the timing of such deductibility. As a result, no March 31, 2018 December 31, 2017 not twelve March 31, 2018, 2014 2017 Benefit from income taxes was $0 three March 31, 2018, 0%, $1.5 three March 31, 2017, 33.7%. three March 31, 2018 2017 2017. As of March 31, 2018, $131.8 $20.4 $9.7

Note 15 - Segments

Note 15 - Segments	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Segment Reporting Disclosure [Text Block]	1 5 . Segments We report information about our operating segments using the “management approach” in accordance with current accounting standards. This information is based on the way management organizes and reports the segments within the enterprise for making operating decisions and assessing performance. Our reportable segments are identified based on differences in products, services and markets served. There were no two 99m NAV4694, The information in the following tables is derived directly from each reportable segment’s financial reporting. T hree Months Ended March 31, 2018 Diagnostics Therapeutics Corporate Total Tc99m tilmanocept royalty revenue $ 795 $ — $ — $ 795 Grant and other revenue 232,436 43,214 — 275,650 Total revenue 233,231 43,214 — 276,445 Cost of goods sold 318 — — 318 Research and development expenses 785,011 213,945 — 998,956 Selling, general and administrative expenses, excluding depreciation and amortization (1) — 8,607 1,729,778 1,738,385 Depreciation and amortization (2) — — 37,987 37,987 Loss from operations (3) (552,098 ) (179,338 ) (1,767,765 ) (2,499,201 ) Other expense (4) — — (4,238,761 ) (4,238,761 ) Net loss (552,098 ) (179,338 ) (6,006,526 ) (6,737,962 ) Total assets, net of depreciation and amortization: United States $ 13,077,979 $ 27,228 $ 5,189,637 $ 18,294,844 International 26,055 — 1,328 27,383 Capital expenditures — — — — T hree Months Ended March 31, 2017 Diagnostics Therapeutics Corporate Total Grant and other revenue $ 571,362 $ 8,668 $ — $ 580,030 Research and development expenses 413,202 292,072 — 705,274 Selling, general and administrative expenses, excluding depreciation and amortization ( 1 ) — 2,521 2,943,123 2,945,644 Depreciation and amortization ( 2 ) — — 76,790 76,790 Income (loss) from operations ( 3 ) 158,160 (285,925 ) (3,019,913 ) (3,147,678 ) Other expense — — (1,171,109 ) (1,171,109 ) Income tax (expense) benefit (53,254 ) 96,273 1,411,153 1,454,172 Net income (loss) from continuing operations 104,906 (189,652 ) (2,779,869 ) (2,864,615 ) Loss from discontinued operations, net of tax (255,861 ) — — (255,861 ) Gain on sale of discontinued operations, net of tax 88,701,501 — — 88,701,501 Net income (loss) 88,550,546 (189,652 ) (2,779,869 ) 85,581,025 Total assets, net of depreciation and amortization: United States $ 9,692,007 $ 897 $ 23,116,511 $ 32,809,415 International 115,279 — 893 116,172 Capital expenditures — — — — ( 1 General and administrative expenses, excluding depreciation and amortization, represent costs that relate to the general administration of the Company and as such are not ( 2 ) Depreciation and amortization is reflected in selling, general and administrative expenses ( $37,987 $76,790 three March 31, 2018 2017, $9,745 three March 31, 2017). ( 3 ) Loss from operations does not ( 4 ) Amounts consist primarily of losses on debt extinguishment and changes in fair value of financial instruments, which are not

Note 16 - Supplemental Disclosu

Note 16 - Supplemental Disclosure for Statements of Cash Flows	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Cash Flow, Supplemental Disclosures [Text Block]	1 6 . Supplemental Disclosure for Statements of Cash Flows During the three March 31, 2018 2017, $3,000 $7.3 three March 31, 2018, 94,684 401 $36,000. three March 31, 2017, 1.0 $334,000.

Note 17 - Subsequent Events

Note 17 - Subsequent Events	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Subsequent Events [Text Block]	1 7 . Subsequent Events The Company has evaluated events and transactions subsequent to March 31, 2018 10 a. Amendment to Asset Purchase Agreement: April 2, 2018, 414 $6.0 not $7.1 414 414 414 b. CRG Litigation: January 16, 2018, $66.0 $4.1 June 2016, $2.9 March 26, 2018, $7.7 April 2, 2018, $4.1 June 2016 $66.0 On April 9, 2018, $7.1 $4.1 $59.0 On April 12, 2018 2017, $66.0 $66.0 $4.1 June 2016 $66.0 $66.0 $7.1 414 no In a related proceeding before the Ohio Court, initially filed in 2016, 2017, $66.0 not $4.1 $4.1 On April 11, 2018, not $7.1 414 April 16, 2018, April 27, 2018. May 2, 2018, May 21, 2018. c. Platinum Litigation: April 30, 2018 no

Significant Accounting Policies

Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2018
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	a. Basis of Presentation: March 31, 2018 three March 31, 2018 2017 March 31, 2018 not December 31, 2017, 10 Our consolidated financial statements include the accounts of Navidea and our wholly owned subsidiaries, Navidea Biopharmaceuticals Limited and Cardiosonix Ltd, as well as those of our majority-owned subsidiary, Macrophage Therapeutics, Inc. (“MT”). All significant inter-company accounts were eliminated in consolidation. Cardiosonix was legally dissolved in September 2017. On March 3, 2017, November 23, 2016 ( 414, 414” ® Upon closing of the Asset Sale, the Supply and Distribution Agreement dated November 15, 2007, 414 no Our consolidated balance sheets and statements of operations have been reclassified, as required, for all periods presented to reflect the Business as a discontinued operation. Cash flows associated with the operation of the Business have been combined with operating, investing and financing cash flows, as appropriate, in our consolidated statements of cash flows. See Note 3. Certain prior period amounts also have been reclassified to conform with the current year’s presentation, including the adoption of Accounting Standards Update (“ASU”) No. 2014 09, Revenue from Contracts with Customers
Fair Value of Financial Instruments, Policy [Policy Text Block]	b. Financial Instruments and Fair Value: 1 3 three Level 1 Level 2 not Level 3 A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. In determining the appropriate levels, we perform a detailed analysis of the assets and liabilities whose fair value is measured on a recurring basis. At each reporting period, all assets and liabilities for which the fair value measurement is based on significant unobservable inputs or instruments which trade infrequently and therefore have little or no 3. 5. The following methods and assumptions were used to estimate the fair value of each class of financial instruments: ( 1 Cash, available-for-sale securities, accounts and other receivables, and accounts payable: March 31, 2018 December 31, 2017, $96,000 2016. ( 2 Notes payable: March 31, 2018 December 31, 2017 March 31, 2018 December 31, 2017, 3 March 31, 2018 December 31, 2017, March 31, 2018, $2.3 $2.3 December 31, 2017, $2.4 $2.4 9. ( 3 Derivative liabilities: $63,000 March 31, 2018 December 31, 2017 March 31, 2018 December 31, 2017 5. ( 4 Warrants: March 2017, 414 five 10 1 $1.50 414 $3.3 three March 31, 2017. $334,000, 13.
Revenue Recognition, Policy [Policy Text Block]	c. Revenue Recognition: We also earn revenues related to our licensing and distribution agreements. The consideration we are eligible to receive under our licensing and distribution agreements typically includes upfront payments, reimbursement for research and development costs, milestone payments, and royalties. Each licensing and distribution agreement is unique and requires separate assessment in accordance with current accounting standards. See Note 4.
New Accounting Pronouncements, Policy [Policy Text Block]	d. Recent ly Adopted Accounting Standards : May 2014, 2014 09, Revenue from Contracts with Customers (Topic 606 2014 09 2014 09 five may 2014 09, 606 2014 09 2014 09 2014 09 December 15, 2017, In March 2016, No. 2016 08, Revenue from Contracts with Customers – Principal versus Agent Considerations (Reporting Revenue Gross versus Net) 2016 08 not 2016 08 No. 2014 09, Revenue from Contracts with Customers (Topic 606 not 2016 08 2014 09, one No. 2015 14, Revenue from Contracts with Customers – Deferral of the Effective Date December 15, 2017, December 15, 2016, In April 2016, No. 2016 10, Revenue from Contracts with Customers – Identifying Performance Obligations and Licensing 2016 10 not 2016 10 No. 2014 09, Revenue from Contracts with Customers (Topic 606 not 2016 10 2014 09, one No. 2015 14, Revenue from Contracts with Customers – Deferral of the Effective Date December 15, 2017, December 15, 2016, In May 2016, No. 2016 12, Revenue from Contracts with Customers – Narrow-Scope Improvements and Practical Expedients 2016 12 not 606, 2016 12 No. 2014 09, Revenue from Contracts with Customers (Topic 606 not 2016 12 2014 09, one No. 2015 14, Revenue from Contracts with Customers – Deferral of the Effective Date December 15, 2017, December 15, 2016, In December 2016, No. 2016 20, Technical Corrections and Improvements to Topic 606, 2016 20 not 606, 606, 2016 20 No. 2014 09, Revenue from Contracts with Customers (Topic 606 not 2016 12 2014 09, one No. 2015 14, Revenue from Contracts with Customers – Deferral of the Effective Date December 15, 2017, December 15, 2016, We adopted ASU 2014 09, 2016 08, 2016 10, 2016 12 2016 20, January 1, 2018 2014 09 $700,000. 4. In November 2016, No. 2016 18, Statement of Cash Flows – Restricted Cash 2016 18 2016 18 December 15, 2017, 2016 18 2016 18 January 1, 2018. 2016 18 $5.0 three March 31, 2017. In March 2018, No. 2018 05, Income Taxes (Topic 740 No. 118. 2018 05 740 No. 118. 2018 05 740 2018 05 March 2018 not

Note 3 - Discontinued Operati26

Note 3 - Discontinued Operations (Tables)	3 Months Ended
	Mar. 31, 2018
Notes Tables
Disposal Groups, Including Discontinued Operations [Table Text Block]	March 31, 2018 December 31, 2017 Accrued liabilities $ — $ 7,092 Liabilities associated with discontinued operations, current $ — $ 7,092 Three Months Ended March 31, 2018 2017 Lymphoseek sales revenue $ — $ 2,917,213 Cost of goods sold — 364,192 Gross profit — 2,553,021 Operating expenses: Research and development — 283,533 Selling, general and administrative — 820,203 Total operating expenses — 1,103,736 Income from discontinued operations — 1,449,285 Interest expense — (1,718,506 ) Loss before income taxes — (269,221 ) Benefit from income taxes — 13,360 Loss from discontinued operations $ — $ (255,861 )

Note 4 - Revenue From Contrac27

Note 4 - Revenue From Contracts With Customers (Tables)	3 Months Ended
	Mar. 31, 2018
Notes Tables
Disaggregation of Revenue [Table Text Block]	T hree Months Ended March 31, 2018 Diagnostics Therapeutics Total Tc99m tilmanocept royalty revenue: Europe $ 795 $ — $ 795 India — — — China — — — Total $ 795 $ — $ 795 Other revenue: Additional stability studies $ 15,037 $ — $ 15,037
Contract with Customer, Asset and Liability [Table Text Block]	Three Months Ended March 31, 2018 2017 Total deferred revenue, beginning of period $ 26,061 $ 41,098 Impact of adoption of ASU 2014-09 and related standards 700,000 — Revenue recognized from satisfaction of performance obligations (15,037 ) (15,037 ) Total deferred revenue, end of period $ 711,024 $ 26,061
Accounting Standards Update 2014-09 [Member]
Notes Tables
Schedule of New Accounting Pronouncements and Changes in Accounting Principles [Table Text Block]	P re - Adoption P ost - Adoption Change Deferred revenue $ 26,061 $ 726,061 $ 700,000 Accumulated deficit (319,908,968 ) (320,608,968 ) (700,000 )

Note 5 - Fair Value (Tables)

Note 5 - Fair Value (Tables)	3 Months Ended
	Mar. 31, 2018
Notes Tables
Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]	Liabilities Measured at Fair Value on a Recurring Basis as of March 31, 201 8 and December 31, 2017 Description Quoted Prices in Active Markets for Identical Liabilities (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Total Liability related to MT warrants $ — $ — $ 63,000 $ 63,000

Note 6 - Stock-based Compensa29

Note 6 - Stock-based Compensation (Tables)	3 Months Ended
	Mar. 31, 2018
Notes Tables
Share-based Compensation, Stock Options, Activity [Table Text Block]	T hree Months Ended March 31, 2018 Number of Options Weighted Average Exercise Price Weighted Average Remaining Contractual Life (years) Aggregate Intrinsic Value Outstanding at beginning of period 3,687,679 $ 1.50 Granted 470,000 0.53 Exercised — — Canceled and Forfeited (5,000 ) 0.51 Expired — — Outstanding at end of period 4,152,679 $ 1.39 6.8 $ — Exercisable at end of period 2,159,746 $ 2.06 4.5 $ —
Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]	Three Months Ended March 31, 2018 Number of Shares Weighted Average Grant-Date Fair Value Unvested at beginning of period 150,000 $ 0.51 Granted 200,000 0.37 Vested (100,000 ) 0.43 Forfeited — — Unvested at end of period 250,000 $ 0.42

Note 7 - Earnings (Loss) Per 30

Note 7 - Earnings (Loss) Per Share (Tables)	3 Months Ended
	Mar. 31, 2018
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Three Months Ended March 31 , 2018 2017 Weighted average shares outstanding, basic 162,269,012 160,376,476 Dilutive shares related to warrants — 4,288,479 Unvested restricted stock — 207,000 Weighted average shares outstanding, diluted 162,269,012 164,871,955

Note 10 - Terminated Lease Li31

Note 10 - Terminated Lease Liability (Tables)	3 Months Ended
	Mar. 31, 2018
Notes Tables
Terminated Lease Liability [Table Text Block]	Terminated Lease Liability Total liability, January 1, 2018 $ 695,307 Changes in estimated future payments (44,755 ) Payments under Blazer lease (93,217 ) Receipts from subtenant 117,373 Accretion of liability 8,690 Total liability, March 31, 2018 $ 683,398

Note 15 - Segments (Tables)

Note 15 - Segments (Tables)	3 Months Ended
	Mar. 31, 2018
Notes Tables
Schedule of Segment Reporting Information, by Segment [Table Text Block]	T hree Months Ended March 31, 2018 Diagnostics Therapeutics Corporate Total Tc99m tilmanocept royalty revenue $ 795 $ — $ — $ 795 Grant and other revenue 232,436 43,214 — 275,650 Total revenue 233,231 43,214 — 276,445 Cost of goods sold 318 — — 318 Research and development expenses 785,011 213,945 — 998,956 Selling, general and administrative expenses, excluding depreciation and amortization (1) — 8,607 1,729,778 1,738,385 Depreciation and amortization (2) — — 37,987 37,987 Loss from operations (3) (552,098 ) (179,338 ) (1,767,765 ) (2,499,201 ) Other expense (4) — — (4,238,761 ) (4,238,761 ) Net loss (552,098 ) (179,338 ) (6,006,526 ) (6,737,962 ) Total assets, net of depreciation and amortization: United States $ 13,077,979 $ 27,228 $ 5,189,637 $ 18,294,844 International 26,055 — 1,328 27,383 Capital expenditures — — — — T hree Months Ended March 31, 2017 Diagnostics Therapeutics Corporate Total Grant and other revenue $ 571,362 $ 8,668 $ — $ 580,030 Research and development expenses 413,202 292,072 — 705,274 Selling, general and administrative expenses, excluding depreciation and amortization ( 1 ) — 2,521 2,943,123 2,945,644 Depreciation and amortization ( 2 ) — — 76,790 76,790 Income (loss) from operations ( 3 ) 158,160 (285,925 ) (3,019,913 ) (3,147,678 ) Other expense — — (1,171,109 ) (1,171,109 ) Income tax (expense) benefit (53,254 ) 96,273 1,411,153 1,454,172 Net income (loss) from continuing operations 104,906 (189,652 ) (2,779,869 ) (2,864,615 ) Loss from discontinued operations, net of tax (255,861 ) — — (255,861 ) Gain on sale of discontinued operations, net of tax 88,701,501 — — 88,701,501 Net income (loss) 88,550,546 (189,652 ) (2,779,869 ) 85,581,025 Total assets, net of depreciation and amortization: United States $ 9,692,007 $ 897 $ 23,116,511 $ 32,809,415 International 115,279 — 893 116,172 Capital expenditures — — — —

Note 1 - Summary of Significa33

Note 1 - Summary of Significant Accounting Policies (Details Textual) - USD ($) $ / shares in Units, shares in Millions	1 Months Ended	3 Months Ended		12 Months Ended
	Mar. 31, 2017	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2017	Jan. 01, 2018
Notes Payable, Fair Value Disclosure		$ 2,300,000		$ 2,400,000
Notes Payable, Current, Total		2,276,926		2,353,639
Derivative Liability, Total		63,000		63,000
Deferred Revenue					$ 726,061
Cumulative Effect of New Accounting Principle in Period of Adoption				(700,000)
Platinum Loan Agreement [Member]
Embedded Derivative, Fair Value of Embedded Derivative Liability		0		0
PPCO [Member] | Platinum Loan Agreement [Member] | Fair Value, Inputs, Level 3 [Member]
Embedded Derivative, Fair Value of Embedded Derivative Liability		0
Retained Earnings [Member]
Cumulative Effect of New Accounting Principle in Period of Adoption				(700,000)
Accounting Standards Update 2014-09 [Member] | Retained Earnings [Member]
Cumulative Effect of New Accounting Principle in Period of Adoption					(700,000)
Accounting Standards Update 2014-09 [Member] | Sayre Pharmaceuticals [Member]
Deferred Revenue					700,000
Accounting Standards Update 2014-09 [Member] | Sayre Pharmaceuticals [Member] | Retained Earnings [Member]
Cumulative Effect of New Accounting Principle in Period of Adoption					$ (100,000)
Accounting Standards Update 2016-18 [Member] | Fiscal Year 2016 [Member]
Prior Period Reclassification Adjustment		5,000,000
Series NN Warrants [Member]
Class of Warrant or Right, Term	5 years
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 1.50		$ 1.50
Series NN Warrants [Member] | Cardinal Health 414 [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	10		10
Class of Warrant or Right, Grants in Period, Estimated Fair Value			$ 3,300,000	3,300,000
Series NN Warrants [Member] | UCSD [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	1		1
Class of Warrant or Right, Grants in Period, Estimated Fair Value			$ 334,000	334,000
Former Executive [Member]
Accounts Payable, Disputed		$ 96,000		$ 96,000

Note 2 - Liquidity (Details Tex

Note 2 - Liquidity (Details Textual) - USD ($)	Apr. 12, 2018	Apr. 09, 2018	Apr. 02, 2018	Mar. 26, 2018	Jan. 16, 2018	Nov. 02, 2017	Mar. 31, 2017	Mar. 03, 2017	Dec. 31, 2017	Mar. 31, 2017
Subsequent Event [Member] | CRG [Member]
Draws on Letter of Credit		$ 7,100,000
Sale of Assets to Cardinal Health 414 [Member] | Subsequent Event [Member]
Sale of Assets, Cash Received from Buyer as Result of Amendment			$ 6,000,000
Sale of Assets, Maximum Amount Receivable from Buyer for Unused Portion of Letter of Credit			$ 7,100,000
PPCO [Member] | Platinum Loan Agreement [Member]
Repayments of Debt								$ 7,700,000
Convertible Debt, Total								1,900,000
Judicial Ruling [Member] | CRG Loan Agreement, Texas Case [Member]
Loss Contingency, Damages Awarded, Value, Additional Amount								7,000,000	$ 7,000,000
Loss Contingency, Damages Awarded, Value, Amount not Taken into Consideration					$ 4,100,000				4,100,000
Loss Contingency, Damages Awarded,Value, Requested Modified Amount					2,900,000
Judicial Ruling [Member] | CRG Loan Agreement, Texas Case [Member] | Surety Bond [Member]
Loss Contingency, Amount Awarded to Other Party				$ 7,700,000
Judicial Ruling [Member] | CRG Loan Agreement, Texas Case [Member] | CRG [Member] | Term Loan Agreement [Member]
Repayments of Debt							$ 59,000,000	59,000,000		$ 59,000,000
Judicial Ruling [Member] | CRG Loan Agreement, Texas Case [Member] | Maximum [Member]
Loss Contingency, Damages Awarded, Value								$ 66,000,000	$ 66,000,000
Pending Litigation [Member] | CRG Loan Agreement, Texas Case [Member]
Loss Contingency, Damages Awarded, Value, Amount not Taken into Consideration					4,100,000
Loss Contingency, Damages Awarded,Value, Requested Modified Amount					$ 2,900,000
Pending Litigation [Member] | CRG Loan Agreement, Ohio Case [Member] | Subsequent Event [Member]
Loss Contingency, Damages Sought, Value	$ 4,100,000
Pending Litigation [Member] | Platinum-Montaur Life Sciences LLC Litigation [Member]
Loss Contingency, Damages Sought, Value						$ 1,900,000

Note 3 - Discontinued Operati35

Note 3 - Discontinued Operations (Details Textual) - USD ($)	Apr. 02, 2018	Mar. 03, 2017	Mar. 31, 2018	Mar. 31, 2017
Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax, Total				$ 88,701,501
Sale of Assets to Cardinal Health 414 [Member]
Sale of Assets, Cash Received from Buyer, After Adjustments, Inventory Transferred		$ 80,600,000
Sale of Assets, Cash Received from Buyer, After Adjustments, Advances of Guaranteed Earnout Payments		$ 3,000,000
Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax, Total				88,700,000
Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax, Guaranteed Consideration				16,500,000
Warrants Issued During Period, Value Issued, Asset Sale				3,300,000
Sale of Assets, Legal and Other Fees Related to the Sale				2,000,000
Sale of Assets, Net Balance Sheet Dispositions and Write-offs				800,000
Discontinued Operation, Tax Effect of Gain (Loss) from Disposal of Discontinued Operation				$ 4,600,000
Sale of Assets to Cardinal Health 414 [Member] | Subsequent Event [Member]
Sale of Assets, Cash Received from Buyer as Result of Amendment	$ 6,000,000
Sale of Assets, Maximum Amount Receivable from Buyer for Unused Portion of Letter of Credit	$ 7,100,000

Note 3 - Discontinued Operati36

Note 3 - Discontinued Operations - Discontinued Operations (Details) - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2017
Accrued liabilities			$ 7,092
Liabilities associated with discontinued operations, current			$ 7,092
Lymphoseek sales revenue		$ 2,917,213
Cost of goods sold		364,192
Gross profit		2,553,021
Operating expenses of discontinued operation:
Research and development		283,533
Selling, general and administrative		820,203
Total operating expenses		1,103,736
Income from discontinued operations		1,449,285
Interest expense		(1,718,506)
Loss before income taxes		(269,221)
Benefit from income taxes		13,360
Loss from discontinued operations		$ (255,861)

Note 4 - Revenue From Contrac37

Note 4 - Revenue From Contracts With Customers (Details Textual) - USD ($)	3 Months Ended
	Mar. 31, 2018	Jan. 01, 2018	Dec. 31, 2017
Cumulative Effect of New Accounting Principle in Period of Adoption			$ (700,000)
Revenue from Contract with Customer, Including Assessed Tax	$ 16,000
Contract with Customer, Asset, Impairment Loss	$ 0
Contract with Customer, Payment Term, Minimum	15 days
Contract with Customer, Payment Term, Maximum	90 days
Contract with Customer, Asset, Net, Total	$ 0
Contract with Customer, Transaction Price of Royalties Using Expected Value Method	0
Capitalized Contract Cost, Net, Total	$ 0
INDIA
Contract with Customer, Term of Contract	8 years
CHINA
Contract with Customer, Term of Contract	10 years
Long-term Contract with Customer [Member]
Contract with Customer, Performance Obligation Satisfied in Previous Period	$ 0
Retained Earnings [Member]
Cumulative Effect of New Accounting Principle in Period of Adoption			$ (700,000)
Accounting Standards Update 2014-09 [Member] | Retained Earnings [Member]
Cumulative Effect of New Accounting Principle in Period of Adoption		$ (700,000)
Accounting Standards Update 2014-09 [Member] | Retained Earnings [Member] | Sayre Pharmaceuticals [Member]
Cumulative Effect of New Accounting Principle in Period of Adoption		(100,000)
Accounting Standards Update 2014-09 [Member] | Retained Earnings [Member] | Beijing Sinotau Medical Research Co., Ltd. [Member]
Cumulative Effect of New Accounting Principle in Period of Adoption		$ (600,000)

Note 4 - Revenue From Contrac38

Note 4 - Revenue From Contracts With Customers - Change in Deferred Revenue and Accumulated Deficit (Details) - USD ($)	Mar. 31, 2018	Jan. 01, 2018	Dec. 31, 2017
Deferred revenue		$ 726,061
Accumulated deficit	$ (327,346,921)	(320,608,968)	$ (319,908,968)
Calculated under Revenue Guidance in Effect before Topic 606 [Member]
Deferred revenue			26,061
Accumulated deficit			$ (319,908,968)
Difference between Revenue Guidance in Effect before and after Topic 606 [Member] | Accounting Standards Update 2014-09 [Member]
Deferred revenue		700,000
Accumulated deficit		$ (700,000)

Note 4 - Revenue From Contrac39

Note 4 - Revenue From Contracts With Customers - Disaggregation of Revenue (Details) - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Revenue from contract with customer	$ 16,000
Royalty [Member]
Revenue from contract with customer	795
Royalty [Member] | Diagnostics Segment [Member]
Revenue from contract with customer	795
Royalty [Member] | Therapeutics Segment [Member]
Revenue from contract with customer
Product and Service, Other [Member]
Revenue from contract with customer	15,037
Product and Service, Other [Member] | Diagnostics Segment [Member]
Revenue from contract with customer	15,037
Product and Service, Other [Member] | Therapeutics Segment [Member]
Revenue from contract with customer
Europe [Member] | Royalty [Member]
Revenue from contract with customer	795
Europe [Member] | Royalty [Member] | Diagnostics Segment [Member]
Revenue from contract with customer	795
Europe [Member] | Royalty [Member] | Therapeutics Segment [Member]
Revenue from contract with customer
INDIA | Royalty [Member]
Revenue from contract with customer
INDIA | Royalty [Member] | Diagnostics Segment [Member]
Revenue from contract with customer
INDIA | Royalty [Member] | Therapeutics Segment [Member]
Revenue from contract with customer
CHINA | Royalty [Member]
Revenue from contract with customer
CHINA | Royalty [Member] | Diagnostics Segment [Member]
Revenue from contract with customer
CHINA | Royalty [Member] | Therapeutics Segment [Member]
Revenue from contract with customer

Note 4 - Revenue From Contrac40

Note 4 - Revenue From Contracts With Customers - Changes in Contract Liabilities (Details) - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Total deferred revenue, beginning of period	$ 26,061	$ 41,098
Impact of adoption of ASU 2014-09 and related standards	700,000
Revenue recognized from satisfaction of performance obligations	(15,037)	(15,037)
Total deferred revenue, end of period	$ 711,024	$ 26,061

Note 5 - Fair Value (Details Te

Note 5 - Fair Value (Details Textual) - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2017	Dec. 31, 2016
Derivative Liability, Total	$ 63,000		$ 63,000
Fair Value, Inputs, Level 1 [Member]
Financial and Nonfinancial Liabilities, Fair Value Disclosure	0	$ 0
Fair Value, Inputs, Level 3 [Member]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease), Total	0	(140,000)
Fair Value, Inputs, Level 2 [Member]
Financial and Nonfinancial Liabilities, Fair Value Disclosure	$ 0	$ 0
Other Liabilities [Member]
Derivative Liability, Total			$ 63,000	$ 63,000

Note 5 - Fair Value - Financial

Note 5 - Fair Value - Financial Liabilities Measured at Fair Value on a Recurring Basis (Details) - USD ($)	Mar. 31, 2018	Dec. 31, 2017
Derivative Liability, Total	$ 63,000	$ 63,000
Fair Value, Measurements, Recurring [Member]
Derivative Liability, Total	63,000
Fair Value, Inputs, Level 1 [Member] | Fair Value, Measurements, Recurring [Member]
Derivative Liability, Total
Fair Value, Inputs, Level 2 [Member] | Fair Value, Measurements, Recurring [Member]
Derivative Liability, Total
Fair Value, Inputs, Level 3 [Member] | Fair Value, Measurements, Recurring [Member]
Derivative Liability, Total	$ 63,000

Note 6 - Stock-based Compensa43

Note 6 - Stock-based Compensation (Details Textual)	1 Months Ended		3 Months Ended
	Mar. 31, 2018USD ($)shares	Sep. 30, 2016$ / sharesshares	Mar. 31, 2018USD ($)shares	Mar. 31, 2017USD ($)
Allocated Share-based Compensation Expense, Total | $			$ 138,000	$ 147,000
Employee Service Share-based Compensation, Tax Benefit from Compensation Expense | $			0	$ 0
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Total | $	$ 195,000		$ 195,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition			1 year 109 days
The 2014 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized | shares	10,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized | shares	15,000,000		15,000,000
Employee Stock Option [Member] | Scenario, Plan [Member] | The 2016 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage		100.00%
Share-based Compensation Arrangement By Share-based Payment Award Award, Vesting, Threshold Consecutive Trading Days		5
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price | $ / shares		$ 2.50
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period		10 years
Employee Stock Option [Member] | Scenario, Plan [Member] | Chief Executive Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures, Total | shares		5,000,000

Note 6 - Stock-based Compensa44

Note 6 - Stock-based Compensation - Summary of Stock Option Activity (Details)	3 Months Ended
	Mar. 31, 2018USD ($)$ / sharesshares
Outstanding at beginning of period (in shares) | shares	3,687,679
Outstanding at beginning of period (in dollars per share) | $ / shares	$ 1.50
Granted (in shares) | shares	470,000
Granted, weighted average exercise price (in dollars per share) | $ / shares	$ 0.53
Exercised (in shares) | shares
Exercised, weighted average exercise price (in dollars per share) | $ / shares
Canceled and Forfeited (in shares) | shares	(5,000)
Canceled and Forfeited, weighted average exercise price (in dollars per share) | $ / shares	$ 0.51
Expired (in shares) | shares
Expired (in dollars per share) | $ / shares
Outstanding at end of period (in shares) | shares	4,152,679
Outstanding at end of period (in dollars per share) | $ / shares	$ 1.39
Outstanding at end of period (Year)	6 years 292 days
Outstanding at end of period | $
Exercisable at end of period (in shares) | shares	2,159,746
Exercisable at end of period (in dollars per share) | $ / shares	$ 2.06
Exercisable at end of period (Year)	4 years 182 days
Exercisable at end of period | $

Note 6 - Stock-based Compensa45

Note 6 - Stock-based Compensation - Summary of Unvested Restricted Stock (Details) - Restricted Stock [Member]	3 Months Ended
	Mar. 31, 2018$ / sharesshares
Unvested at beginning of period (in shares) | shares	150,000
Unvested at beginning of period (in dollars per share) | $ / shares	$ 0.51
Granted (in shares) | shares	200,000
Granted, weighted average grant-date fair value (in dollars per share) | $ / shares	$ 0.37
Vested (in shares) | shares	(100,000)
Vested, weighted average grant-date fair value (in dollars per share) | $ / shares	$ 0.43
Forfeited (in shares) | shares
Forfeited, weighted average grant-date fair value (in dollars per share) | $ / shares
Unvested at end of period (in shares) | shares	250,000
Unvested at end of period (in dollars per share) | $ / shares	$ 0.42

Note 7 - Earnings (Loss) Per 46

Note 7 - Earnings (Loss) Per Share (Details Textual) - shares	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Stock Options, Warrants, Convertible Debt, and Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	15,000,000	15,900,000
Restricted Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	250,000	207,000

Note 7 - Earnings (Loss) Per 47

Note 7 - Earnings (Loss) Per Share - Earnings (Loss) Per Share (Details) - shares	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Weighted average shares outstanding, basic (in shares)	162,269,012	160,376,476
Dilutive shares related to warrants (in shares)		4,288,479
Unvested restricted stock (in shares)		207,000
Weighted average shares outstanding, diluted (in shares)	162,269,012	164,871,955

Note 8 - Accounts Payable, Ac48

Note 8 - Accounts Payable, Accrued Liabilities and Other (Details Textual) - USD ($)	Mar. 31, 2018	Dec. 31, 2017
Executive Bonuses, Director Fees, Deferred Salary, and Scientific Advisory Board Fees [Member] | Accrued Liabilities and Other [Member]
Due to Related Parties, Current, Total	$ 956,000	$ 975,000
Former Executive [Member]
Accounts Payable, Disputed	$ 96,000	$ 96,000

Note 9 - Notes Payable (Details

Note 9 - Notes Payable (Details Textual) - USD ($)	Apr. 12, 2018	Apr. 09, 2018	Mar. 26, 2018	Jan. 16, 2018	Nov. 02, 2017	Mar. 31, 2017	Mar. 03, 2017	Dec. 31, 2017	Nov. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Mar. 31, 2018	Mar. 31, 2017	Jul. 31, 2012
Notes Payable, Current, Total								$ 2,353,639				$ 2,276,926
Interest Expense, Debt, Total												44,000	$ 1,700,000
Interest Expense Recorded Related to Amortization of Debt Discounts and Deferred Financing Costs												42,000	143,000
Subsequent Event [Member] | CRG [Member]
Draws on Letter of Credit		$ 7,100,000
Platinum-Montaur Life Sciences LLC Litigation [Member] | Pending Litigation [Member]
Loss Contingency, Damages Sought, Value					$ 1,900,000
CRG Loan Agreement, Texas Case [Member] | Pending Litigation [Member]
Loss Contingency, Damages Awarded, Value, Amount not Taken into Consideration				$ 4,100,000
Loss Contingency, Damages Awarded,Value, Requested Modified Amount				2,900,000
CRG Loan Agreement, Texas Case [Member] | Judicial Ruling [Member]
Loss Contingency, Damages Awarded, Value, Additional Amount							$ 7,000,000	7,000,000
Loss Contingency, Damages Awarded, Value, Amount not Taken into Consideration				4,100,000				4,100,000
Loss Contingency, Damages Awarded,Value, Requested Modified Amount				$ 2,900,000
CRG Loan Agreement, Texas Case [Member] | Judicial Ruling [Member] | Surety Bond [Member]
Loss Contingency, Amount Awarded to Other Party			$ 7,700,000
CRG Loan Agreement, Texas Case [Member] | Judicial Ruling [Member] | Maximum [Member]
Loss Contingency, Damages Awarded, Value							66,000,000	66,000,000
CRG Loan Agreement, Ohio Case [Member] | Pending Litigation [Member] | Subsequent Event [Member]
Loss Contingency, Damages Sought, Value	$ 4,100,000
Platinum Loan Agreement [Member]
Interest Expense, Debt, Excluding Amortization												42,000	143,000
Convertible Debt, Fair Value Disclosures								2,000,000				2,100,000
Embedded Derivative, Fair Value of Embedded Derivative Liability								0				0
Notes Payable Issued for Prepayment of Insurance Premiums [Member]
Notes Payable, Current, Total								$ 318,000				200,000
Notes Payable Issued for Prepayment of Insurance Premiums [Member] | IPFS [Member]
Debt Instrument, Face Amount									$ 396,000		$ 348,000
Debt Instrument, Interest Rate, Stated Percentage									4.00%		8.99%
Debt Instrument, Term									300 days		240 days
Debt Instrument, Periodic Payment, Total									$ 40,000		$ 45,000
PPCO [Member] | Platinum Loan Agreement [Member]
Line of Credit Facility, Maximum Borrowing Capacity														$ 50,000,000
Repayments of Debt							7,700,000
Convertible Debt, Total							1,900,000
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease), Total												$ 0	$ (140,000)
CRG [Member] | Term Loan Agreement [Member] | CRG Loan Agreement, Texas Case [Member] | Judicial Ruling [Member]
Repayments of Debt						$ 59,000,000	$ 59,000,000			$ 59,000,000

Note 10 - Terminated Lease Li50

Note 10 - Terminated Lease Liability (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2017	Mar. 31, 2018	Jun. 01, 2017
Gain (Loss) on Contract Termination	$ (399,000)
Lease Termination of Blazer [Member]
Terminated Lease Liability	695,307	$ 683,398	$ 1,000,000
Lease Termination of Blazer [Member] | Selling, General and Administrative Expenses [Member]
Gain (Loss) on Disposition of Assets, Total	$ (706,000)

Note 10 - Terminated Lease Li51

Note 10 - Terminated Lease Liability - Summary of Changes in Terminated Lease Liability (Details) - Lease Termination of Blazer [Member]	3 Months Ended
	Mar. 31, 2018USD ($)
Total liability, January 1, 2018	$ 695,307
Changes in estimated future payments	(44,755)
Payments under Blazer lease	(93,217)
Receipts from subtenant	117,373
Accretion of liability	8,690
Total liability, March 31, 2018	$ 683,398

Note 11 - Commitments and Con52

Note 11 - Commitments and Contingencies (Details Textual) - USD ($)	Apr. 12, 2018	Apr. 09, 2018	Mar. 26, 2018	Jan. 16, 2018	Nov. 02, 2017	Mar. 31, 2017	Mar. 03, 2017	Dec. 31, 2017	Mar. 31, 2017
CRG [Member] | Subsequent Event [Member]
Draws on Letter of Credit		$ 7,100,000
CRG Loan Agreement, Texas Case [Member] | Judicial Ruling [Member]
Loss Contingency, Damages Awarded, Value, Additional Amount							$ 7,000,000	$ 7,000,000
Loss Contingency, Damages Awarded, Value, Amount not Taken into Consideration				$ 4,100,000				4,100,000
Loss Contingency, Damages Awarded,Value, Requested Modified Amount				2,900,000
CRG Loan Agreement, Texas Case [Member] | Judicial Ruling [Member] | Surety Bond [Member]
Loss Contingency, Amount Awarded to Other Party			$ 7,700,000
CRG Loan Agreement, Texas Case [Member] | Pending Litigation [Member]
Loss Contingency, Damages Awarded, Value, Amount not Taken into Consideration				4,100,000
Loss Contingency, Damages Awarded,Value, Requested Modified Amount				$ 2,900,000
CRG Loan Agreement, Ohio Case [Member] | Pending Litigation [Member] | Subsequent Event [Member]
Loss Contingency, Damages Sought, Value	$ 4,100,000
Platinum-Montaur Life Sciences LLC Litigation [Member] | Pending Litigation [Member]
Loss Contingency, Damages Sought, Value					$ 1,900,000
Maximum [Member] | CRG Loan Agreement, Texas Case [Member] | Judicial Ruling [Member]
Loss Contingency, Damages Awarded, Value							66,000,000	$ 66,000,000
CRG [Member] | Term Loan Agreement [Member] | CRG Loan Agreement, Texas Case [Member] | Judicial Ruling [Member]
Repayments of Debt						$ 59,000,000	59,000,000		$ 59,000,000
CRG [Member] | Term Loan Agreement [Member] | Maximum [Member]
Debt Instrument, Agreed-upon Final Payoff Amount							$ 66,000,000

Note 12 - Equity Instruments (D

Note 12 - Equity Instruments (Details Textual) - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Stock Issued During Period, Shares, Employee Benefit Plan	94,684
Issuance of Stock to Defined Contribution Plan for Employer Matching Contribution	$ 35,980
Common Stock [Member]
Stock Issued During Period, Shares, Employee Benefit Plan	94,684
Employees [Member] | Common Stock [Member]
Stock Issued During Period, Shares, Issued for Services	458,401	707,353
Stock Issued During Period, Value, Issued for Services	$ 165,000	$ 368,000
Director [Member] | Common Stock [Member]
Stock Issued During Period, Shares, Issued for Services	0	16,406
Stock Issued During Period, Value, Issued for Services	$ 0	$ 10,500

Note 13 - Stock Warrants (Detai

Note 13 - Stock Warrants (Details Textual) - USD ($)	1 Months Ended		3 Months Ended		12 Months Ended
	Mar. 31, 2017	Jan. 31, 2017	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2017
Series NN Warrants [Member]
Class of Warrant or Right, Term	5 years
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 1.50			$ 1.50
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate	77.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate	2.00%
Series NN Warrants [Member] | Cardinal Health 414 [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	10,000,000			10,000,000
Class of Warrant or Right, Grants in Period, Estimated Fair Value				$ 3,300,000	$ 3,300,000
Series NN Warrants [Member] | UCSD [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	1,000,000			1,000,000
Class of Warrant or Right, Grants in Period, Estimated Fair Value				$ 334,000	$ 334,000
Warrants to Purchase Navidea Common Stock [Member]
Class of Warrant or Right, Outstanding			16,900,000
Warrants to Purchase Navidea Common Stock [Member] | Minimum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 0.01
Class of Warrant or Right, Outstanding Term			90 days
Warrants to Purchase Navidea Common Stock [Member] | Maximum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 3.04
Class of Warrant or Right, Outstanding Term			17 years
Warrants to Purchase Navidea Common Stock [Member] | Weighted Average [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 1.19
Warrants to Purchase MT Common Stock [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 2,000
Class of Warrant or Right, Outstanding			300
Chief Executive Officer [Member]
Class of Warrant or Right, Exercises in Period		5,411,850
Stock Issued During Period, Shares, Issued for Exercise of Warrants		5,411,850
Proceeds from Warrant Exercises		$ 54,119

Note 14 - Income Taxes (Details

Note 14 - Income Taxes (Details Textual) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2017
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	21.00%		35.00%
Unrecognized Tax Benefits, Ending Balance	$ 0		$ 0
Open Tax Year	2014 2015 2016 2017
Income Tax Expense (Benefit), Total	$ 0	$ (1,454,172)
Effective Income Tax Rate Reconciliation, Percent, Total	0.00%	33.70%
Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member]
Operating Loss Carryforwards, Total	$ 131,800,000
Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member] | Research Tax Credit Carryforward [Member]
Tax Credit Carryforward, Amount	9,700,000
State and Local Jurisdiction [Member]
Operating Loss Carryforwards, Total	20,400,000
Other Noncurrent Assets [Member]
Deferred Tax Assets, Tax Credit Carryforwards, Alternative Minimum Tax	$ 1,200,000		$ 1,200,000

Note 15 - Segments (Details Tex

Note 15 - Segments (Details Textual)		3 Months Ended
		Mar. 31, 2018USD ($)	Mar. 31, 2017USD ($)
Number of Primary Types of Products Sold		2
Depreciation, Depletion and Amortization, Nonproduction, Total	[1]	$ 37,987	$ 76,790
Depreciation and Amortization, Discontinued Operations			9,745
Selling, General and Administrative Expenses [Member]
Depreciation, Depletion and Amortization, Nonproduction, Total		$ 37,987	$ 76,790
[1]	Depreciation and amortization is reflected in selling, general and administrative expenses ($37,987 and $76,790 for the three-month periods ended March 31, 2018 and 2017, and $9,745 was included in discontinued operations for the three-month period ended March 31, 2017).

Note 15 - Segments - Segment In

Note 15 - Segments - Segment Information (Details) - USD ($)		3 Months Ended
		Mar. 31, 2018		Mar. 31, 2017	Dec. 31, 2017
Tc99m tilmanocept royalty revenue		$ 16,000
Grant and other revenue		275,650		$ 580,030
Revenue		276,445		580,030
Cost of goods sold		318
Research and development expenses		998,956		705,274
Selling, general and administrative expenses, excluding depreciation and amortization	[1]	1,738,385		2,945,644
Depreciation, Depletion and Amortization, Nonproduction, Total	[2]	37,987		76,790
Loss from operations	[3]	(2,499,201)		(3,147,678)
Other expense		(4,238,761)	[4]	(1,171,109)
Net income (loss)		(6,737,962)		85,581,025
Total assets, net of depreciation and amortization		18,322,227			$ 20,781,436
Capital expenditures
Income tax (expense) benefit		0		1,454,172
Net income (loss) from continuing operations		(6,737,962)		(2,864,615)
Loss from discontinued operations				(255,861)
Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax, Total				88,701,501
UNITED STATES
Total assets, net of depreciation and amortization		18,294,844		32,809,415
Non-US [Member]
Total assets, net of depreciation and amortization		27,383		116,172
Diagnostics Segment [Member]
Grant and other revenue		232,436		571,362
Revenue		233,231
Cost of goods sold		318
Research and development expenses		785,011		413,202
Selling, general and administrative expenses, excluding depreciation and amortization	[1]
Depreciation, Depletion and Amortization, Nonproduction, Total	[2]
Loss from operations	[3]	(552,098)		158,160
Other expense			[4]
Net income (loss)		(552,098)		88,550,546
Capital expenditures
Income tax (expense) benefit				(53,254)
Net income (loss) from continuing operations				104,906
Loss from discontinued operations				(255,861)
Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax, Total				88,701,501
Diagnostics Segment [Member] | UNITED STATES
Total assets, net of depreciation and amortization		13,077,979		9,692,007
Diagnostics Segment [Member] | Non-US [Member]
Total assets, net of depreciation and amortization		26,055		115,279
Therapeutics Segment [Member]
Grant and other revenue		43,214		8,668
Revenue		43,214
Cost of goods sold
Research and development expenses		213,945		292,072
Selling, general and administrative expenses, excluding depreciation and amortization	[1]	8,607		2,521
Depreciation, Depletion and Amortization, Nonproduction, Total	[2]
Loss from operations	[3]	(179,338)		(285,925)
Other expense			[4]
Net income (loss)		(179,338)		(189,652)
Capital expenditures
Income tax (expense) benefit				96,273
Net income (loss) from continuing operations				(189,652)
Loss from discontinued operations
Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax, Total
Therapeutics Segment [Member] | UNITED STATES
Total assets, net of depreciation and amortization		27,228		897
Therapeutics Segment [Member] | Non-US [Member]
Total assets, net of depreciation and amortization
Corporate Segment [Member]
Grant and other revenue
Revenue
Cost of goods sold
Research and development expenses
Selling, general and administrative expenses, excluding depreciation and amortization	[1]	1,729,778		2,943,123
Depreciation, Depletion and Amortization, Nonproduction, Total	[2]	37,987		76,790
Loss from operations	[3]	(1,767,765)		(3,019,913)
Other expense		(4,238,761)	[4]	(1,171,109)
Net income (loss)		(6,006,526)		(2,779,869)
Capital expenditures
Income tax (expense) benefit				1,411,153
Net income (loss) from continuing operations				(2,779,869)
Loss from discontinued operations
Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax, Total
Corporate Segment [Member] | UNITED STATES
Total assets, net of depreciation and amortization		5,189,637		23,116,511
Corporate Segment [Member] | Non-US [Member]
Total assets, net of depreciation and amortization		1,328		893
Royalty [Member]
Tc99m tilmanocept royalty revenue		795
Royalty [Member] | Diagnostics Segment [Member]
Tc99m tilmanocept royalty revenue		795
Royalty [Member] | Therapeutics Segment [Member]
Tc99m tilmanocept royalty revenue
Royalty [Member] | Corporate Segment [Member]
Tc99m tilmanocept royalty revenue
[1]	General and administrative expenses, excluding depreciation and amortization, represent costs that relate to the general administration of the Company and as such are not currently allocated to our individual reportable segments, other than those expenses directly incurred by MT.
[2]	Depreciation and amortization is reflected in selling, general and administrative expenses ($37,987 and $76,790 for the three-month periods ended March 31, 2018 and 2017, and $9,745 was included in discontinued operations for the three-month period ended March 31, 2017).
[3]	Loss from operations does not reflect the allocation of certain selling, general and administrative expenses, excluding depreciation and amortization, to our individual reportable segments, other than those expenses directly incurred by MT.
[4]	Amounts consist primarily of losses on debt extinguishment and changes in fair value of financial instruments, which are not currently allocated to our individual reportable segments.

Note 16 - Supplemental Disclo58

Note 16 - Supplemental Disclosure for Statements of Cash Flows (Details Textual) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2017
Interest Paid, Excluding Capitalized Interest, Operating Activities		$ 7,300,000
Stock Issued During Period, Shares, Employee Benefit Plan	94,684
Issuance of Stock to Defined Contribution Plan for Employer Matching Contribution	$ 35,980
Series NN Warrants [Member] | UCSD [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		1,000,000
Class of Warrant or Right, Grants in Period, Estimated Fair Value		$ 334,000	$ 334,000

Note 17 - Subsequent Events (De

Note 17 - Subsequent Events (Details Textual) - USD ($) $ in Millions	Apr. 12, 2018	Apr. 09, 2018	Apr. 02, 2018	Mar. 26, 2018	Jan. 16, 2018	Mar. 03, 2017	Dec. 31, 2017
CRG Loan Agreement, Texas Case [Member] | Judicial Ruling [Member]
Loss Contingency, Damages Awarded, Value, Amount not Taken into Consideration					$ 4.1		$ 4.1
Loss Contingency, Damages Awarded,Value, Requested Modified Amount					2.9
CRG Loan Agreement, Texas Case [Member] | Judicial Ruling [Member] | Surety Bond [Member]
Loss Contingency, Amount Awarded to Other Party				$ 7.7
CRG Loan Agreement, Texas Case [Member] | Judicial Ruling [Member] | Maximum [Member]
Loss Contingency, Damages Awarded, Value						$ 66	$ 66
CRG Loan Agreement, Texas Case [Member] | Pending Litigation [Member]
Loss Contingency, Damages Awarded, Value, Amount not Taken into Consideration					4.1
Loss Contingency, Damages Awarded,Value, Requested Modified Amount					$ 2.9
Subsequent Event [Member] | CRG [Member]
Draws on Letter of Credit		$ 7.1
Subsequent Event [Member] | CRG Loan Agreement, Ohio Case [Member] | Pending Litigation [Member]
Loss Contingency, Damages Sought, Value	$ 4.1
Sale of Assets to Cardinal Health 414 [Member] | Subsequent Event [Member]
Sale of Assets, Cash Received from Buyer as Result of Amendment			$ 6
Sale of Assets, Maximum Amount Receivable from Buyer for Unused Portion of Letter of Credit			$ 7.1